A recent study by Pillay et al. in ovarian cancer cells has also revealed that the response to DNA repair inhibitors such as those targeting PARP or PARG may be dependent on DNA replication vulnerabilities in ovarian cancer cells 35. Here, PARG is linked to ovarian cancer.